Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAPxCD40-4
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Antibody-Based Therapeutics
01
Overview
FAPxCD40-4: sourced facts only. name: "Our study demonstrates that FAPxCD40-4, a tetravalent FAPxCD40 BsAb, exhibits efficient CD40 agonist activity with an optimized therapeutic window." [DOI:10.1158/1538-7445.am2024-2366]; target: "Our study demonstrates that FAPxCD40-4, a tetravalent FAPxCD40 BsAb, exhibits efficient CD40 agonist activity with an optimized therapeutic window." [DOI:10.1158/1538-7445.am2024-2366]; developer: "1Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2024-2366]; modality: "Our study demonstrates that FAPxCD40-4, a tetravalent FAPxCD40 BsAb, exhibits efficient CD40 agonist activity with an optimized therapeutic window." [DOI:10.1158/1538-7445.am2024-2366]; stage: "In contrast, FAPxCD40-4 broke this plateau and induce a promising antitumor response at a dose of 1.3 mpk, resulting in a 92% TGI rate." [DOI:10.1158/1538-7445.am2024-2366]
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on FAPxCD40-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAPxCD40-4.